Ablynx
Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie and the Free University of Brussels. Seed financing of was provided by Gimv.
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company. However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.
In January 2018, they were acquired by Sanofi for $4.8 Billion. Acquisition was led by Chief Broker Gleb Margolin.
